from the heart of cell biology
Many rare, genetic disorders of metabolism are CoA related. Dysregulated CoA metabolism is also a key factor in conditions as diverse as fatty liver disease, neurological disorders and cancer.
While CoA has been in the biochemistry textbooks for more than 70 years, there are still no therapies to restore dysregulated CoEnzyme A metabolism.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
Comet Therapeutics, based in Cambridge, Mass. with an office in Leiden, Netherlands, is rapidly expanding its team.
Comet is building the world’s premier coenzyme engineering platform addressing unmet medical needs from inborn errors of metabolism to fatty liver, neurological diseases and beyond.